In contrast to high-power, high-heat lasers that are used in various surgical procedures, the LipoLaser™ produces a low-level, or cold, output that has no thermal effect on the body’s tissue. Instead, the non-invasive laser helps the body absorb fat by stimulating biological function. Excess fat is then removed naturally by the body without the negative side effects and downtime associated with more invasive procedures such as liposuction.

Renowned plastic surgeon Rodrigo Neira, M.D. who participated in the pilot study explains, “Extensive research shows that fat congregates in interstitial spaces for a certain amount of time.” The ZERONA™™ laser stimulates the body to rid itself of that excess fat using the body’s normal processes. We were amazed with the results after using the laser on patients over a period of just two weeks.”

In addition to the completed pilot study, a double blind, randomized, multi-site and placebo controlled study is currently underway. Already the results are consistent with the previous pilot study; in two weeks of treatment, patients are losing as much as nine inches, and an average of over five and a half inches, compared to the placebo group that’s losing on average a half inch.

Erchonia® lasers have achieved FDA market clearance (510K) for liposuction in 2004, acne in 2005, chronic pain in 2001, and for breast augmentation in April 2008.

About the protocol in the clinical trial: Placebo patients were treated with a 635nm L.E.D. The test group was treated with the Erchonia® LipoLaser™. All patients were treated six times over two weeks. Patients were instructed not to restrict their diets. Patients did not feel pain during the non-invasive treatment, did not receive anesthesia, and assumed normal activities after each treatment.